ArticleClinicoEconomics and outcomes research : CEOR2025

Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model.

Ziyad Saeed Almalki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.